Microbot Medical (MBOT) Shares Rise as LIBERTY System Completes World-First Robotic Procedures

Key Facts

1Emory Healthcare successfully completed robotic peripheral endovascular procedures using Microbot Medical's LIBERTY system.

2The procedures included the world's first robotic Prostatic Artery Embolization (PAE) and robotic Y-90 radioembolization mapping for liver cancer.

3The cases demonstrate the adoption of the LIBERTY system across multiple complex medical case types.

Microbot Medical (Nasdaq: MBOT) announced that Emory Healthcare has successfully completed a series of robotic peripheral endovascular procedures using its LIBERTY Endovascular Robotic System. These procedures included the world's first robotic Prostatic Artery Embolization (PAE), marking a significant milestone in minimally invasive surgery. Additionally, the system was utilized for robotic Y-90 radioembolization mapping, a critical step in treating complex liver cancer cases. The successful outcomes demonstrate the clinical versatility and adoption of the LIBERTY system across various complex medical scenarios. This achievement validates Microbot Medical's technology as it moves toward broader commercialization in the global medical robotics market. Investors view this clinical progress as a positive indicator for the company's future growth and market penetration.

Open on chart